LAWRENCE, Mass., Feb. 19, 2013 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced CE Mark approval for nocturnal home hemodialysis with the NxStage System One™. With CE Mark approval, the NxStage System One is continuing its leadership in home hemodialysis technology. NxStage expects to begin marketing the System One for nocturnal dialysis in countries that recognize the CE Mark approval process in the second half of 2013.
Nocturnal dialysis, performed while the patient is sleeping, usually between three and five nights per week, allows much greater time on dialysis without additional inconvenience to the patient or their family. Dialyzing while sleeping has many benefits, but also unique risks; NxStage's nocturnal indication shows the Company's leadership in safety and ease of use by minimizing those risks to the satisfaction of regulators.
"This is an important milestone for NxStage as it provides another example of our leadership in home hemodialysis," said Jeffrey Burbank, Chief Executive Officer, NxStage Medical, Inc. "This approval gives us the unique ability to offer patients and nephrologists greater therapeutic flexibility and an expanded paradigm for dialysis treatment with the System One."About the NxStage System OneThe NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the U.S. Food & Drug Administration (FDA). Its simplicity and revolutionary size (just over a foot tall) provide convenient use in patients' homes and give patients the freedom to travel with their therapy. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, at home or on the road. The NxStage System One is not specifically cleared in the US for nocturnal home hemodialysis. The Company is currently in a trial to support this indication.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV